PubMed Health⌕ Search

Biomedical subjects

H C Falkson

Publications and source records attributed to H C Falkson.

At least 73 records · Page 4Linked to original sources
PubMed1976

Fluorouracil, methyl-CCNU and vincristine in cancer of the colon.

In a randomized study 91 patients with metastatic cancer of the colon were treated with either fluorouracil alone or a combination of fluorouracil, methyl-CCNU, and vincristine. Of those treated with the three-drug combination, 37% responded, and of those treated with fluorouracil alone, 22% responded. Median response duration for patients treated with the combination method was 5.0 months and for those with fluorouracil alone, 3.8 months. Toxic effects are also compared. From this study it is concluded that a three-drug regimen provides a definite advantage.

Clinical Trials as Topic↗
PubMed1976

Phase II trial of cytembena in patients with advanced ovarian and breast cancer.

Thirty women with histologically proven advanced ovarian or breast cancer were treated with cytembena. Of nine patients with ovarian cancer and 21 with breast cancer none had worthwhile objective remissions. Cytembena was given at a dose of 250 mg/m2/day for a course of 5 days repeated at weekly intervals. Improvement, particularly relief of pain from skeletal metastases, was observed in 16 of the patients; an additional seven patients had stable disease while treated with cytembena. Cytembena has no hemopoietic toxicity, but nausea and vomiting and an "autonomic storm" phenomenon are dose-limiting factors. Further studies incorporating this drug in combination regimens seem warranted.

Acrylates↗
PubMed1975

Towards curative treatment of advanced Hodgkin's disease.

Advanced Hodgkin's disease was considered incurable until 1966. The development of combined chemotherapy has led to intensIVe treatment and to cures. Results obtained in 104 patients treated according to acute leukaemia group B protocols are discussed. Staging according to the Rye classification was used, as these patients were treated from 1966 to 1971. Methodology and dosage schemes are discussed. Reponse rates reached 88%, with extended survival. The modifications of therapeutic schedules which led to long-term, unmaintained remissions, are explained. The 5-year survival rate of patients with Hodgkin's disease in stages III and iv who responded, was 82,7%. The effect of histological subclassification on the prognosis is considered. The importance of accurate documentation is stressed, and also the use of laparotomy to prove the staging of the disease so as not to deny the patient the benefit of potential cure with chemotherapy.

Chlorambucil↗
PubMed1975

A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.

A clinical trial of the oral form of VP 16-213 (NSC-141540), a semisynthetic podophyllotoxin, was undertaken. In 20 patients, treatment was started at 200 mg/day p.o. for 5 days; courses were repeated after a rest period of 16 days. Five patients were treated at the same dose, repeated with only 9-day rest periods. Subsequently, 65 patients were given 300-400 mg/day for 5 days, with rest periods of 9 days between courses. The side effects encountered included anorexia, nausea and vomiting, stomatitis, diarrhea, leukopenia, thrombocytopenia, alopecia, and pruritus. Substernal discomfort with or without palpitations was reported by 18 patients; no explanation for this symptom could be found. No complete remissions (CR) were observed. Parital remissions (PR) and improvement (IMP) were seen as follows: small cell carcinoma, lung (10 patients)--2 PR, 3 IMP; adenocarcinoma, lung (4 patients)--1 PR; alveolar cell carcinoma, lung (1 patient)--1 IMP; mesothelioma (4 patients)--1 IMP; ovarian cancer (12 patients)--3 PR, 3 IMP; breast cancer (20 patients)--4 IMP; colon cancer (8 patients)--2 IMP; bladder cancer (4 patients)--2 IMP; histiocytic lymphoma (7 patients)--2 PR, 3 IMP; chronic myeloid leukemia (1 patient)--1 IMP.

Adenocarcinoma↗